Escherichia coli-based cell-free synthesis of virus-like particles

Biotechnology and Bioengineering

Volumn 100, Issue 1, 2008, Pages 28-37

  Bundy, Bradley C ^a   Franciszkowicz, Marc J ^a   Swartz, James R ^a  

^a Stanford University   (United States)

Author keywords

Cell free protein synthesis; Hepatitis B; MS2; Virus like particles; VLP

Indexed keywords

CELLS; DRUG DELIVERY; PROTEINS; VACCINES; VIRUSES;

CELL-FREE PROTEIN SYNTHESIS; LOW-YIELDING PRODUCTION TECHNOLOGIES; MATERIAL SCIENCE APPLICATIONS; PRODUCTION YIELDS;

ESCHERICHIA COLI;

COAT PROTEIN; HEPATITIS B CORE ANTIGEN;

ARTICLE; CELL FREE SYSTEM; CELL PH; DIFFERENTIAL SCANNING CALORIMETRY; ESCHERICHIA COLI; MS2 VIRUS; PROKARYOTE; PROTEIN SYNTHESIS; TRANSMISSION ELECTRON MICROSCOPY; VIRUS CAPSID; VIRUS LIKE AGENT;

CELL-FREE SYSTEM; ESCHERICHIA COLI; LEVIVIRUS; PROTEIN ENGINEERING; RECOMBINANT PROTEINS; TRANSFECTION; VIRION;

ESCHERICHIA COLI; PROKARYOTA;

EID: 42549090557     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.21716     Document Type: Article

References (48)

1. Abramoff MD, Magelhaes PJ, Ram SJ. 2004. Image processing with ImageJ. Biophotonics Intl 11(7):36-42.
2. Alimov AP, Khmelnitsky AY, Simonenko PN, Spirin AS, Chetverin AB. 2000. Cell-free synthesis and affinity isolation of proteins on a nanomole scale. Biotechniques 28(2):338-344.
3. Allen M, Bulte JWM, Liepold L, Basu G, Zywicke HA, Frank JA, Young M, Douglas T. 2005. Paramagnetic viral nanoparticles as potential high-relaxivity magnetic resonance contrast agents. Magn Reson Med 54(4):807-812.
4. Ashcroft AE, Lago H, Macedo JM, Horn WT, Stonehouse NJ, Stockley PG. 2005. Engineering thermal stability in RNA phage capsids via disulphide bonds. J Nanosci Nanotechnol 5(12):2034-2041.
5. Bachmann MF, Jennings GT. 2004. Virus-like particles: Combining innate and adaptive immunity for effective vaccination. In: Kaufmann SHE, editor. Novel vaccination strategies. Weinheim: WILEY-VCH Verlag GmbH & Co. KGaA, pp. 415-430.
6. Blum AS, Soto CM, Wilson CD, Cole JD, Kim M, Gnade B, Chatterji A, Ochoa WF, Lin TW, Johnson JE, et al. 2004. Cowpea mosaic virus as a scaffold for 3-D patterning of gold nanoparticles. Nano Lett 4(5):867-870.
7. Bonner PH. 1974. Intermediates of bacteriophage-Ms2 assembly in vivo. J Virol 14(5):1152-1168.
8. Brown WL, Mastico RA, Wu M, Heal KG, Adams CJ, Murray JB, Simpson JC, Lord JM, Taylor-Robinson AW, Stockley PG. 2002. RNA bacteriophage capsid-mediated drug delivery and epitope presentation. Intervirology 45(6):371-380.
9. Calhoun KA, Swartz JR. 2005. An economical method for cell-free protein synthesis using glucose and nucleoside monophosphates. Biotechnol Progr 21(4):1146-1153.
10. Ceres P, Zlotnick A. 2002. Weak protein-protein interactions are sufficient to drive assembly of hepatitis B virus capsids. Biochemistry 41(39):11525-11531.
11. Douglas T, Young M. 2006. Viruses: Making friends with old foes. Science 312(5775):873-875.
12. Grodberg J, Dunn JJ. 1988. Ompt encodes the Escherichia-coli outer-membrane protease that cleaves T7-RNA polymerase during purification. J Bacteriol 170(3):1245-1253.
13. Hooker JM, Kovacs EW, Francis MB. 2004. Interior surface modification of bacteriophage MS2. J Am Chem Soc 126(12):3718-3719.
14. Hoover DM, Lubkowski J. 2002. DNAWorks: An automated method for designing oligonucleotides for PCR-based gene synthesis. Nucleic Acids Res 30(10):E43.
15. Jewett MC. 2005. The impact of cytoplasmic mimicry on cell-free biology. PhD Thesis. Stanford, CA: Stanford University.
16. Jewett MC, Swartz JR. 2004a. Mimicking the Escherichia coli cytoplasmic environment activates long-lived and efficient cell-free protein synthesis. Biotechnol Bioeng 86(1):19-26.
17. Jewett MC, Swartz JR. 2004b. Rapid expression and purification of 100 nmol quantities of active protein using cell-free protein synthesis. Biotechnol Progr 20(1):102-109.
18. Kiga D, Sakamoto K, Kodama K, Kigawa T, Matsuda T, Yabuki T, Shirouzu M, Harada Y, Nakayama H, Takio K, et al. 2002. An engineered Escherichia coli tyrosyl-tRNA synthetase for site-specific incorporation of an unnatural amino acid into proteins in eukaryotic translation and its application in a wheat germ cell-free system. Proc Natl Acad Sci USA 99(15):9715-9720.
19. Kosinski M. 2006. American Chemical Society Industrial Biotechnology Award Presentation. 11 Sep 2006. San Francisco, CA.
20. Kratz PA, Bottcher B, Nassal M. 1999. Native display of complete foreign protein domains on the surface of hepatitis B virus capsids. Proc Natl Acad Sci USA 96(5):1915-1920.
21. Lechner F, Jegerlehner A, Tissot AC, Maurer P, Sebbel P, Renner WA, Jennings GT, Bachmann MF. 2002. Virus-like particles as a modular system for novel vaccines. Intervirology 45(4-6):212-217.
22. Legendre D, Fastrez J. 2005. Production in Saccharomyces cerevisiae of MS2 virus-like particles packaging functional heterologous mRNAs. J Biotechnol 117(2):183-194.
23. Lingappa JR, Newman MA, Klein KC, Dooher JE. 2005. Comparing capsid assembly of primate lentiviruses and hepatitis B virus using cell-free systems. Virology 333(1):114-123.
24. Liu DV, Zawada JF, Swartz JR. 2005. Streamlining Escherichia coli S30 extract preparation for economical cell-free protein synthesis. Biotechnol Progr 21(2):460-465.
25. Mastico RA, Talbot SJ, Stockley PG. 1993. Multiple presentation of foreign peptides on the surface of an RNA-free spherical bacteriophage capsid. J Gen Virol 74:541-548.
26. Maurer P, Bachmann MF. 2006. Therapeutic vaccines for nicotine dependence. Curr Opin Mol Ther 8(1):11-16.
27. Nath N, Hickman K, Nowlan S, Shah D, Phillips J, Babler S. 1992. Stability of the recombinant hepatitis-B core antigen. J Clin Microbiol 30(6):1617-1619.
28. Pasek M, Goto T, Gilbert W, Zink B, Schaller H, Mackay P, Leadbetter G, Murray K. 1979. Hepatitis-B virus genes and their expression in Escherichia-coli. Nature 282(5739):575-579.
29. Pattenden LK, Middelberg APJ, Niebert M, Lipin DI. 2005. Towards the preparative and large-scale precision manufacture of virus-like particles. Trends Biotechnol 23(10):523-529.
30. Peabody DS. 1997. Role of the coat protein-RNA interaction in the life cycle of bacteriophage MS2. Mol Gen Genet 254(4):358-364.
31. Peabody DS. 2003. A viral platform for chemical modification and multivalent display. J Nanobiotechnol 1 5.
32. Pickett GG, Peabody DS. 1993. Encapsidation of heterologous RNAs by bacteriophage-MS2 coat protein. Nucleic Acids Res 21(19):4621-4626.
33. Pumpens P, Grens E. 2001. HBV core particles as a carrier for B cell/T cell epitopes. Intervirology 44(2-3):98-114.
34. Reddy ST, Swartz MA, Hubbell JA. 2006. Targeting dendritic cells with biomaterials: Developing the next generation of vaccines. Trends Immunol 27(12):573-579.
35. Rohrmann GF, Krueger RG. 1970. Physical, biochemical, and immunological properties of coliphage MS-2 particles. J Virol 6(3):269-279.
36. Rothengass BE. 2007. Advocating for the quadravalent HPV vaccination, Gardasil, by Merck. Int J Pediatr Otorhi 71(4):671-672.
37. Shenton W, Douglas T, Young M, Stubbs G, Mann S. 1999. Inorganic-organic nanotube composites from template mineralization of tobacco mosaic virus. Adv Mater 11(3):253-256.
38. Shtatland T, Gill SC, Javornik BE, Johansson HE, Singer BS, Uhlenbeck OC, Zichi DA, Gold L. 2000. Interactions of Escherichia coli RNA with bacteriophage MS2 coat protein: Genomic SELEX. Nucleic Acids Res 28(21):E93.
39. Stiege W, Erdmann VA. 1995. The potentials of the in vitro protein biosynthesis system. J Biotechnol 41(2-3):81-90.
40. Suttle CA. 2005. Viruses in the sea. Nature 437(7057):356-361.
41. Underwood KA, Swartz JR, Puglisi JD. 2005. Quantitative polysome analysis identifies limitations in bacterial cell-free protein synthesis. Biotechnol Bioeng 91(4):425-435.
42. Voloshin AM. 2006. Principles and applications of cell-free protein synthesis systems scale-up. PhD Thesis. Stanford, CA: Stanford University.
43. Voloshin AM, Swartz JR. 2005. Efficient and scalable method for scaling up cell free protein synthesis in batch mode. Biotechnol Bioeng 91(4):516-521.
44. Voloshin AM, Swartz JR. 2007. Large-scale batch reactions for cell-free protein synthesis. In: Spirin AS, Swartz JR, editors. Cell-free protein synthesis: methods and protocols. Weinheim: Wiley-VCH Verlag GmbH & Co. KGaA. p. 207-235.
45. Wingfield PT, Stahl SJ, Williams RW, Steven AC. 1995. Hepatitis core antigen produced in Escherichia-coli - Subunit composition, conformational- analysis, and in-vitro capsid assembly. Biochemistry 34(15):4919-4932.
46. Woodrow KA, Airen IO, Swartz JR. 2006. Rapid expression of functional genomic libraries. J Proteome Res 5(12):3288-3300.
47. Wu M, Brown WL, Stockley PG. 1995. Cell-specific delivery of bacteriophage-encapsidated Ricin A Chain. Bioconjugate Chem 6:587-595.
48. Zlotnick A, Cheng N, Conway JF, Booy FP, Steven AC, Stahl SJ, Wingfield PT. 1996. Dimorphism of hepatitis B virus capsids is strongly influenced by the c-terminus of the capsid protein. Biochemistry 35(23):7412-7421.